3737.HK WACC - Weighted Average Cost of Capital

The WACC of Zhongzhi Pharmaceutical Holdings Ltd (3737.HK) is 9.0%.

The Cost of Equity of Zhongzhi Pharmaceutical Holdings Ltd (3737.HK) is 10.40%.

The Cost of Debt of Zhongzhi Pharmaceutical Holdings Ltd (3737.HK) is 4.25%.

	Range	Selected
Cost of equity	8.50% - 12.30%	10.40%
Tax rate	17.70% - 19.30%	18.50%
Cost of debt	4.00% - 4.50%	4.25%
WACC	7.5% - 10.6%	9.0%

WACC

3737.HK WACC calculation

Category	Low	High

Long-term bond rate	2.9%	3.4%
Equity market risk premium	6.0%	7.0%
Adjusted beta	0.94	1.21

Additional risk adjustments	0.0%	0.5%
Cost of equity	8.50%	12.30%

Tax rate	17.70%	19.30%
Debt/Equity ratio	0.25	0.25
Cost of debt	4.00%	4.50%

After-tax WACC	7.5%	10.6%


Selected WACC	9.0%

3737.HK's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 3737.HK:

cost_of_equity (10.40%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (0.94) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.